GSE183113
S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating PI3K/AKT signaling pathway
We performed PCSK9 knockdown or treated with PCSK9 inhibitors in HepG2 cells along with RNA sequencing. Overall design: RNA sequencing in HepG2 cells with shControl, shPCSK9, DMSO and PCSK9 inhibitors.